Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Investor Presentation (March 2026)
18 slides from Chimeric Therapeutics's investor presentation, Mar 25, 2026
Slide 1: Chimeric Therapeutics: Pioneers in Cell Therapy
For personal use only CHIMERIC CHI ME RI C T HERA PEUT IC S PIONEERS IN CELL THERAPY ASX: CHM 20 26 C H IM ERI C TH ERAP EUT IC S. C OM
Slide 2: Disclaimer
2 DISCLAIMER Certain statements contained in this presentation, prior to their approval of our products. including, without limitation, statements containing the Given these uncertainties, undue reliance should not be For personal use only words “believes,” “plans,” “expects,” “anticipates,” and pla
Slide 3: Investment Overview and Corporate Profile
3 INVESTMENT OVERVIEW 3 3 Phase 1 clinical trials For personal use only CORPORATE PROFILE Exchange ASX: CHM CHI ME RI C T HERA PEUT IC S Multiple clinical updates Share Price $0.002 Experienced leadership team 52 Week Range 0 $0.001 - 0.009 Market Cap ~ 8.8m the FIRST CDH17 CAR-T in clinical trials
Slide 4: CHM: Focused Portfolio of Novel Cell Therapies
4 CHM: FOCUSED PORTFOLIO 2 Novel cell therapies; 3 Clinical Trials For personal use only CHM CDH17 CHM CORE-NK ‘OFF THE SHELF’ NK CHI ME RI C T HERA PEUT IC S CAR-T PHASE 1B TRIAL PHASE 1B TRIAL SUSPENDED PHASE 1/2 TRIAL OPEN OPEN 4 sites active MD Anderson Case Western C H IM ERI C TH ERAP EUT IC S
Slide 5: CHM CDH17
For personal use only CHI ME RI C T HERA PEUT IC S CHM CDH17 ASX: CHM 20 26 C H IM ERI C TH ERAP EUT IC S. C OM
Slide 6: Encouraging Pre-Clinical Results
6 ENCOURAGING PRE-CLINICAL RESULTS CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models For personal use only NEUROENDOCRINE TUMOURS GASTRIC CANCER CHI ME RI C T HERA PEUT IC S PANCREATIC CANCER CHM CDH17 CAR-T Source: Feng et al., Nature Cancer, 2022 C H IM ERI
Slide 7: CHM CDH17 CAR-T Phase 1/2 Recruiting
7 CHM CDH17 CAR-T PHASE 1 RECRUITING The first CDH17 CAR T cell therapy in clinical trials globally For personal use only PERSONALISED CAR-T: AUTOLOGOUS CHM CDH17 4 sites actively recruiting: Sarah Cannon, UPenn, UChicago, Emory CAR-T FDA IND November 2023 CHI ME RI C T HERA PEUT IC S First Patient
Slide 8: Phase 1/2 Clinical Trial of CHM CDH17
Phase 1/2 Clinical Trial of CHM CDH17 For personal use only CHI ME RI C T HERA PEUT IC S OPEN COMPLETE OPEN COMPLETE NCT06055439 C H IM ERI C TH ERAP EUT IC S. C OM
Slide 9: CHM CDH17 Progress as at March 23, 2026
9 CHM CDH17 PROGRESS AS AT MARCH 23, 2026 For personal use only Dose Level Status Notes 1 50m Completed 4 patients treated 1 patient remains on study CHI ME RI C T HERA PEUT IC S 2 150m Recruitment completed 5 patients treated – all achieved SD at Day 28 1 awaiting treatment 3 450m Recruitment under
Slide 10: Total Global Market Size
10 TOTAL GLOBAL MARKET SIZE For personal use only CHI ME RI C T HERA PEUT IC S 27.7Bin 2024 C H IM ERI C TH ERAP EUT IC S. C OM
Slide 11: Summary: CHM CDH17
SUMMARY 11 patients treated, 1 awaiting treatment For personal use only 12/12 manufacturing runs CHM CDH17 Anti-tumour activity observed CHM 2101 No safety issues to date CHI ME RI C T HERA PEUT IC S No off-target effects Complete Dose level 2 Commence Dose level 3 Conclude Phase 1 Phase 2 readiness
Slide 12: CHM CORE NK
For personal use only CHI ME RI C T HERA PEUT IC S CHM CORE NK ASX: CHM 20 26 C H IM ERI C TH ERAP EUT IC S. C OM
Slide 13: CHM CORE-NK Phase 1b Trials Open
13 CHM CORE-NK 2 PHASE 1B TRIALS OPEN Phase 1b clinical trials OPEN For personal use only OFF THE SHELF: ALLOGENEIC CHM CORE-NK NK cell expansion platform: Universal Donor ‘OFF THE SHELF’ NK CHI ME RI C T HERA PEUT IC S Positive Phase 1A Clinical Trial in AML Two ongoing Phase 1B Clinical Trials in
Slide 14: AML Phase 1b Clinical Trial Open
14 AML PHASE 1B CLINICAL TRIAL OPEN CHM CORE-NK + AZA + VEN in FRONTLINE AML Clinical Trials.gov Identifier: NCT05834244 For personal use only CHI ME RI C T HERA PEUT IC S CORE NK CELLS FDA REGISTERED FDA REGISTERED CHEMOTHERAPY BLOOD CANCER DRUG CHM CORE NK ‘OFF THE SHELF’ NK C H IM ERI C TH ERAP E
Slide 15: CHM CORE-NK FrontLine Phase 1b Study Results
15 CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS Four Completes Responses, 1 Partial Response For personal use only Dose escalation Relapse Refractory Patients completed 1 Complete Response CHI ME RI C T HERA PEUT IC S First line FrontLine Patients with no prior treatment Dosing 3 Complete Responses U
Slide 16: Summary: CHM CORE-NK
16 SUMMARY CHM CORE-NK For personal use only Investigator Sponsored Trial – MD ANDERSON CHM CORE-NK Dose Escalation completed CHM CDH17 ‘OFF THE SHELF’ NK CHM 2101 First Line Dosing Underway – up to 20 patients CHI ME RI C T HERA PEUT IC S No safety issues to date Complete dosing of 20 patients; sub
Slide 17: Summary
SUMMARY 11 patients treated For personal use only 12/12 manufacturing runs CHM CDH17 Tumour shrinkage observed 10 CHM 2101 No unexpected safety issues to date CHI ME RI C T HERA PEUT IC S No off-target effects Investigator Sponsored Trial – MD ANDERSON Dose Escalation completed CHM CORE-NK First Lin
Slide 18: Chimeric: Pioneers in Cell Therapy
For personal use only CHIMERIC CHI ME RI C T HERA PEUT IC S PIONEERS IN CELL THERAPY investors@chimerictherapeutics.Com ASX: CHM 20 26 C H IM ERI C TH ERAP EUT IC S. C OM
Chimeric Therapeutics — Investor Presentation (March 2026) on 6ix